Dianthus Therapeutics宣布参加9月三场投资者会议，属例行公告，无增量催化

该公告仅为Dianthus Therapeutics参加三场投资者会议的例行通知，不含任何新临床数据、监管决定、合作、订单、财务指引或管线更新。投资者会议参会公告是上市公司日常信息披露，对股价无增量影响，不构成任何方向的交易催化。

📄 原文GlobeNewswire Biotechnology↗ 原文

Dianthus Therapeutics to Participate in Three Investor Conferences During September

NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-…

不做 Dianthus Therapeutics（DNTH.US）

投资者会议参会公告属上市公司例行信息披露，不含任何新临床数据、监管进展、合作、财务指引或管线更新，无增量催化，无方向，无edge，不构成交易机会

展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Dianthus Therapeutics（DNTH.US）于2026年9月1日通过GlobeNewswire发布公告，宣布CEO和CFO将在9月8-10日参加Wells Fargo、Citi和Cantor三场投资者会议并主持一对一会议和炉边谈话。该公告属于上市公司标准投资者关系活动通知，未披露任何新临床数据、监管进展、商业合作、财务指引或管线里程碑。此类公告在美股市场每日大量出现，对股价无增量信息价值，不存在可交易的方向性催化。结论：不做。

🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗

先例如何影响了这次决策

对本次决策的影响:事件本身不构成催化，无需先例校准

方向:无先例可用

涨幅量级:无先例可用

形态:无先例可用

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0

search_processed_events 成功 stock_tools HTTP · 498 ms
{"result": "search_processed_events:agent query=`dianthus therapeutics investor conference | dianthus wells fargo citi cantor | dnth conference participation september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 62.4/72 小时、2202 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}

原文全文

展开原文 · 1,643 字

NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences.
Wells Fargo 21st Annual Healthcare Conference:
Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.
Citi's 2026 Biopharma Back to School Conference:
Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetings.
2026 Cantor Global Healthcare Conference:
Marino Garcia will participate in a fireside chat on Thursday, September 10, 2026, at 8:35 a.m. ET and host one-on-one investor meetings.
Webcasts of the presentations at the Citi and Cantor conferences may be accessed under “News and Events” in the
Investors
section of the Dianthus Therapeutics
website
.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit
www.dianthustx.com
and follow us on
LinkedIn
.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。